Insulet Corporation
PODD · NASDAQ · USD · Healthcare
1What is happening
Insulet Corporation has fallen 13% since its 6-week high on 05/11/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayfrom the 6-week high-13.0%
Other view · 23 analystsHorizon: 12 months15 Buy · 11 Hold · 0 Sell2Our assessment
Dip in progress45How it continues – phase and signs – you see with a free account.
3Your next step
Marking places no order – it only helps you keep track.
More details · reasons, figures, alerts
How deep is the dip?
- from the 6-week high-13.0%
Highest daily price: $168.47 on 05/11/2026 · reference of the assessment · also the highest of the last 3 months
- from the 52-week high-58.7%
Highest price in 52 weeks: $354.88 (Yahoo)
Why is it down?
quarterly numbers- ·From its 6-week high of $168.47 on 05/11/2026 the price fell 13.0% to $146.51.
- ·The biggest single-day drop was 6.2% on 06/11/2026.
- ·That was right after the quarterly numbers. Results were 25% above expectations, so the market reacted to the outlook or details, not the headline number.
- ·No clear news driver in the last 10 days.
- ·The whole market is down 5.6% from its 60-day high, so part of this is not about the company.
- ·Other Medical Devices stocks we track are down only 5.4% on average, so this is mostly about the company. See all 77 in this sector →
Drops after numbers usually take a few weeks to settle. The score already accounts for the miss.
What analysts expect
23 analysts disagree. They look about 12 months ahead – DipCatcher only 14 trading days.
- Buy
- 1558 %
- Hold
- 1142 %
- Sell
- 00 %
Average price target$178.35
$160.00 to $200.00 · today $146.51
$160.00Ø $178.35$200.00
What is a price target?
The price an analyst expects in about 12 months. Estimates are often far apart and change frequently.
Third-party opinion, not an assessment by DipCatcher. Source: public analyst estimates, as of 08/11/2026. Not financial advice.
The company in figures
- Market value
- 10.2 bn $
- All shares together at the current price.
- P/E
- 23.9
- Price divided by earnings per share, last 12 months.
- 52-week range
- $126.40 – $354.88
- Lowest and highest price of the last year.
Catalysts
35 h ago- News, last 10 days
- no recent news
- Next earnings
- —
- Last report
- 04/11/2026 +25.4% vs estimate
Key figures
- Market value
- 10.2 bn $Large cap
- P/E
- 23.9
- Volume today
- 1.0 × Øabout usual
- Beta
- 1.05swings about like the market
- 52-week range
- $126.40 – $354.88price at 9 % of the range
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Headquarters:
- Acton, United States
- 52-week range:
- $126.40 – $354.88
- Website:
- insulet.com
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
See which stocks they are
The engine is watching these dips right now. A free account shows the names and opens 3 full analyses a day.
- 3 full analyses a dayWith entry, target, stop and the reasons behind them.
- WatchlistFollow the stocks you care about.
Free, no payment details.
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
Not investment advice. Investing carries risk up to total loss.